Tangram Therapeutics Announces Appointment of Laura Roca-Alonso, Ph.D. as Interim Chief Executive Officer

London, UK, 30 March 2026 – Tangram Therapeutics (“Tangram”), a company committed to uniting computation and RNAi to make better medicines faster, today announced that Ali Mortazavi has stepped down as Chief Executive Officer for personal reasons. The Board of Directors has appointed Laura Roca-Alonso, Ph.D., who has served as Tangram’s Chief Operating and Business Officer since April 2020, as Interim Chief Executive Officer, effective immediately.

“On behalf of the Board, I would like to thank Ali for his leadership and contributions to Tangram. Under his direction, the company developed and advanced its GalOmic RNAi platform, building a strong foundation for future growth,” said Lord David Prior, Chair of the Board of Directors. “As the Company enters its next phase, we are pleased to appoint Laura as interim CEO. Since joining Tangram, Laura has played a central role in building and leading the organization. Her appointment ensures Tangram continues to execute on its strategic priorities.”

Laura Roca-Alonso added, “I am honored to take on the role of interim CEO at this important time for Tangram. I look forward to continuing to work closely with our team to advance our differentiated pipeline and deliver on key milestones, including initial clinical data from TGM-312 for MASH and the clinical entry of TGM-148 for bleeding disorders during 2026.”

Dr. Roca-Alonso has broad-ranging experience in genetic medicines spanning strategy, business development, and operations. Over the past six years, she has been instrumental in transforming Tangram’s operating model and positioning, driving in-house platform development and pipeline progression into the clinic. Prior to Tangram, she held senior roles at Silence Therapeutics (NASDAQ: SLN) and Gyroscope Therapeutics (acquired by Novartis). Laura holds a Ph.D. from Imperial College London.

Ali Mortazavi commented, “It has been a privilege to lead Tangram and work alongside such a talented team. Laura has been an integral part of the company’s progress, and I have every confidence in her leadership as Tangram enters its next phase.”

About Tangram Therapeutics 

Tangram Therapeutics is a clinical-stage biotech company committed to uniting computation, RNAi, and unconventional thinking to make better medicines faster. We are advancing a pipeline of GalOmic RNAi medicines for a broad range of diseases with high unmet need.

Tangram’s innovative medicines are enabled by GalOmic, our proprietary RNAi chemistry platform designed to selectively silence disease-driving genes in hepatocytes. Discovery is powered by LLibra OS, our next-generation AI platform with an agentic infrastructure. The unique combination of these platforms is the foundation of our Relentless Medicine Discovery. Faster, smarter development of RNAi medicines designed for real-world impact.

Learn more at www.tangramtx.com.

Media Contact
press@tangramtx.com

Investor Relations Contact
IR@tangramtx.com